Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

261
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
261
Hepatic Portal System01:21

Hepatic Portal System

5.6K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.6K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

219
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
219
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

199
Body:Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
199
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

542
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
542
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

305
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
305

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biological responses of human astrocytes (SVGp12) and glioblastoma (A172) cells to dendronized β-cyclodextrin molecular containers: Morphological and molecular insights.

Bioorganic chemistry·2026
Same author

Molecular Characterization of Helicase and Nuclease Domains in PPV5 NS1 from Mexican Full-Length Sequence.

Viruses·2026
Same author

Evidence of SARS-CoV-2 Exposure in Rodents from Rural Localities in the Yucatan Peninsula, Mexico.

Viruses·2026
Same author

Respiratory virus dynamics in a tropical region: Insights from Yucatán, México (2018-2024).

Epidemiology and infection·2026
Same author

Correction to: The wild plant Gnaphalium lavandulifolium as a sentinel for biomonitoring the effects of environmental heavy metals in the metropolitan area of México Valley.

Environmental monitoring and assessment·2025
Same author

Comparison of the genotoxic and epigenetic effects induced by the herbicide glyphosate and a commercial formulation in the bronchial cell line NL20.

Chemosphere·2025

Related Experiment Video

Updated: Jan 23, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.6K

Hepatitis E in Latin America.

Rosa Elena Sarmiento-Silva1, Francisco Arenas-Huertero2

  • 1Departamento de Microbiología e Inmunología, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Ciudad de México, México.

Annals of Hepatology
|June 7, 2019
PubMed
Summary

Hepatitis E virus (HEV) is an emerging health concern, particularly in the USA and Latin America. Limited epidemiological data and varied symptoms hinder accurate assessment and management of HEV infections.

Keywords:
Hepatitis ELatin AmericaLiver diseaseVirus infections

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.9K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Related Experiment Videos

Last Updated: Jan 23, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.6K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.9K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Area of Science:

  • Virology
  • Epidemiology
  • Public Health

Background:

  • Hepatitis E virus (HEV) represents a significant and growing global health challenge.
  • Epidemiological data on HEV infections in the USA and Latin America remain notably scarce.
  • The diverse clinical presentations of HEV contribute to underdiagnosis and underestimation of its true seroprevalence.

Purpose of the Study:

  • To highlight the emerging public health issue posed by Hepatitis E virus.
  • To underscore the limited understanding of HEV epidemiology in specific regions.
  • To emphasize the importance of clinical and diagnostic accuracy in managing HEV.

Main Methods:

  • This study is a review of current literature on Hepatitis E virus.
  • Analysis of existing epidemiological data from the USA and Latin America.
  • Discussion of clinical manifestations and diagnostic challenges.

Main Results:

  • Hepatitis E virus infections are an increasing concern with limited epidemiological surveillance in the Americas.
  • The broad spectrum of clinical symptoms associated with HEV leads to significant underestimation of infection rates.
  • Accurate diagnosis and clinical evaluation are crucial for effective patient care.

Conclusions:

  • There is a critical need for enhanced epidemiological studies on Hepatitis E virus in the USA and Latin America.
  • Improving diagnostic tools and clinical recognition is essential to accurately gauge and address the HEV burden.
  • Effective patient management strategies depend on a better understanding of HEV's epidemiology and clinical impact.